Search

By causing inflammation and tissue damage, neutrophil extracellular traps (NETs) constitute an underlying mechanism of aspiration-induced lung injury, a major factor of the low utilization of donor lungs in lung transplantation (LTx). To determine whether NET removal during ex vivo lung perfusion (EVLP) can restore lung function and morphology in aspiration-damaged lungs, gastric aspiration lung injury was induced in 12 pigs. After confirmation of acute respiratory distress syndrome, the lungs were explanted and assigned to NET removal connected to EVLP (treated) (n = 6) or EVLP only (nontreated) (n = 6). Hemodynamic measurements were taken, and blood and tissue samples were collected to assess lung function, morphology, levels of cell-free DNA, extracellular histones, and nucleosomes as markers of NETs, as well as cytokine levels. After EVLP and NET removal in porcine lungs, PaO 2 /FiO 2 ratios increased significantly compared to those undergoing EVLP alone (p = 0.0411). Treated lungs had lower cell-free DNA (p = 0.0260) and lower levels of extracellular histones in EVLP perfusate (p = 0.0260) than nontreated lungs. According to histopathology, treated lungs showed less immune cell infiltration and less edema compared with nontreated lungs, which was reflected in decreased levels of proinflammatory cytokines in EVLP perfusate and bronchoalveolar lavage fluid. To conclude, removing NETs during EVLP improved lung function and morphology in aspiration-damaged donor lungs. The ability to remove NETs during EVLP could represent a new therapeutic approach for LTx and potentially expand the donor pool for transplantation. [ABSTRACT FROM AUTHOR]

To evaluate donor gamete utilization, patient satisfaction, and fertility treatment outcomes of patients pursuing treatment with donor gametes stratified by the desired race as well as ethnicity of the gamete donor. Survey study. Clinic. Patients planning to undergo treatment using donor sperm and/or donor oocytes at a single academic fertility clinic in the Southeastern United States between 2015 and 2020. None. Utilization rates of donor gametes, satisfaction with donor gamete selection, and fertility treatment outcomes stratified by race and ethnicity of patient, as well as that of their gamete donor. Four hundred fifty patients were eligible for inclusion and 170 (38%) responded to the survey. Among the respondents, 59% desired a non-Hispanic White gamete donor and 20% desired a non-Hispanic Black gamete donor. Patients seeking a non-Hispanic Black gamete donor had lower odds of using donor gametes (Odds ratio [OR], 0.13; 95% confidence interval [CI], 0.04–0.40) compared with individuals seeking a non-Hispanic White gamete donor. When evaluating satisfaction with donor gamete selection, patients seeking a non-Hispanic Black gamete donor reported lower satisfaction compared with individuals seeking a non-Hispanic White gamete donor (OR, 0.19; 95% CI, 0.09–0.43). When evaluating fertility outcomes, Non-Hispanic Black patients and those using non-Hispaninc Black gamete donors were found to have lower odds of successful conception compared with non-Hispanic White patients (OR, 0.18; 95% CI, 0.07–0.46) and individuals seeking non-Hispanic White gamete donors (OR, 0.26; 95% CI, 0.09–0.75), respectively. Patients seeking non-Hispanic Black donor gametes have lower utilization rates, less satisfaction with gamete donor selection, and lower odds of conception when compared with those seeking non-Hispanic White gamete donors. These findings highlight the need for more racial diversity within donor gamete banks, as well as within the donor pools available through agencies and fertility clinics. [ABSTRACT FROM AUTHOR]

In 2016, we initiated a quality improvement endeavor to increase pediatric heart offer acceptance. This study assessed the effect of these interventions at our center. We evaluted pre- and postimplementation cohorts (January 1, 2008-December 31, 2016 vs January 1, 2017-July 1, 2023) comparing donor heart utilization. Six interventions were iterated over time to increase offer acceptance ("extended criteria"): ABO-incompatible transplant, ex vivo perfusion for distanced donors, 3-dimensional total cardiac volume (TCV) assessment, acceptance of hepatitis-C or Severe Acute Respiratory Syndrome Coronavirus 2 infected donors, and institutional culture change favoring consideration of donors previously considered unacceptable. Outcomes studied included annual HT volume, median waitlist duration, sequence number at acceptance, and post-transplant clinical outcomes. During the study period, annual transplant volume increased from 16/year to 25/year pre- and postimplementation. Three hundred thirteen of 389 (80%) listed patients were transplanted. Waitlist duration shortened postimplementation (p = 0.01), as did the percentage of accepted heart offers utilizing at least 1 extended criterion (p < 0.001). Institutional culture change and TCV assessment had the largest impact on donor heart utilization (p = 0.04 and p < 0.001). There was no difference in post-HT intubation or intensive care unit days (p = 0.05-0.9), though post-transplant hospitalization duration (p < 0.001) increased. Post-transplant survival was unaffected by the use of extended criteria hearts (p = 0.3). We report a successful longitudinal, multifaceted effort to increase organ offer utilization, with institutional culture change and TCV assessments most impactful. The use of extended criteria hearts was not associated with inferior survival. [ABSTRACT FROM AUTHOR]

Systemic lupus erythematosus (SLE) is usually regarded as a relative contraindication for deceased kidney donation. The pathological variations because of the changes in the immune environment after kidney transplantation (KT) are unclear, and the recovery of renal function is poorly understood. We present a case of KT from a deceased donor with SLE who was followed-up for one year. Although SLE-related hemangioma developed during the perioperative period, it was cured after interventional treatment. A pre-planned biopsy was performed one year after KT, and it was found that most of the pathological changes and immunofluorescent markers of lupus had resolved. Renal function was stable, and urinary protein and occult blood levels reduced one year after KT. [ABSTRACT FROM AUTHOR]

Autologous costal cartilage has gained widespread acceptance as an important material for ear reconstruction in patients with microtia. Despite its recognition as being "worth the trade-off," attention should be directed toward donor-site deformities. This systematic review focused on existing English literature related to microtia reconstruction and aimed to reveal the incidence of chest wall deformities and assess the effectiveness of the various proposed surgical techniques aimed at reducing donor-site morbidities. A comprehensive search was conducted on Pubmed and OVID using the keywords "microtia," and "chest deformity" or "rib harvest." Articles were screened based on predefined inclusion and exclusion criteria. Data acquisition encompassed patient demographics, employed surgical techniques, methods for evaluating chest deformity, and incidence of associated complications. Among the 362 identified articles, 21 met the inclusion criteria. A total of 2600 cases involving 2433 patients with microtia were analyzed in this review. Perichondrium preservation during cartilage harvesting led to a significant reduction in chest deformities. However, the wide incidence range (0% to 50%) and the lack of specific assessment methods suggested potential underestimation. Computed tomography revealed reduced chest wall growth in the transverse and sagittal directions, resulting in decreased thoracic area. Innovative surgical techniques have shown promising results in reducing chest deformities. Although a quantitative analysis was not feasible, objective evidence of deformities was established through computed tomography scans. This analysis highlighted the need for dedicated studies with larger sample sizes to further advance our understanding of chest wall deformities in microtia reconstruction. [ABSTRACT FROM AUTHOR]

Transplantation of hearts from hepatitis C virus (HCV)-positive donors has increased substantially in recent years following development of highly effective direct-acting antiviral therapies for treatment and cure of HCV. Although historical data from the pre–direct-acting antiviral era demonstrated an association between HCV-positive donors and accelerated cardiac allograft vasculopathy (CAV) in recipients, the relationship between the use of HCV nucleic acid test–positive (NAT+) donors and the development of CAV in the direct-acting antiviral era remains unclear. We performed a retrospective, single-center observational study comparing coronary angiographic CAV outcomes during the first year after transplant in 84 heart transplant recipients of HCV NAT+ donors and 231 recipients of HCV NAT– donors. Additionally, in a subsample of 149 patients (including 55 in the NAT+ cohort and 94 in the NAT– cohort) who had serial adjunctive intravascular ultrasound examination performed, we compared development of rapidly progressive CAV, defined as an increase in maximal intimal thickening of ≥0.5 mm in matched vessel segments during the first year post-transplant. In an unadjusted analysis, recipients of HCV NAT+ hearts had reduced survival free of CAV ≥1 over the first year after heart transplant compared with recipients of HCV NAT– hearts. After adjustment for known CAV risk factors, however, there was no significant difference between cohorts in the likelihood of the primary outcome, nor was there a difference in development of rapidly progressive CAV. These findings support larger, longer-term follow-up studies to better elucidate CAV outcomes in recipients of HCV NAT+ hearts and to inform post-transplant management strategies. [Display omitted] [ABSTRACT FROM AUTHOR]

Primary graft dysfunction (PGD) is the leading cause of early morbidity and mortality after lung transplantation. Accurate prediction of PGD risk could inform donor approaches and perioperative care planning. We sought to develop a clinically useful, generalizable PGD prediction model to aid in transplant decision-making. We derived a predictive model in a prospective cohort study of subjects from 2012 to 2018, followed by a single-center external validation. We used regularized (lasso) logistic regression to evaluate the predictive ability of clinically available PGD predictors and developed a user interface for clinical application. Using decision curve analysis, we quantified the net benefit of the model across a range of PGD risk thresholds and assessed model calibration and discrimination. The PGD predictive model included distance from donor hospital to recipient transplant center, recipient age, predicted total lung capacity, lung allocation score (LAS), body mass index, pulmonary artery mean pressure, sex, and indication for transplant; donor age, sex, mechanism of death, and donor smoking status; and interaction terms for LAS and donor distance. The interface allows for real-time assessment of PGD risk for any donor/recipient combination. The model offers decision-making net benefit in the PGD risk range of 10% to 75% in the derivation centers and 2% to 10% in the validation cohort, a range incorporating the incidence in that cohort. We developed a clinically useful PGD predictive algorithm across a range of PGD risk thresholds to support transplant decision-making, posttransplant care, and enrich samples for PGD treatment trials. [ABSTRACT FROM AUTHOR]

Transplantation is a definitive treatment of choice in suitable patients with end-stage organ failure. Approximately 5000 heart transplants and 4000 lung transplants are performed globally every year. Survival after heart transplant is almost twice in comparison to lung transplant. Due to deficiency in donor pool, number of patients on waiting list are increasing every year. Recipient selection should be done carefully as it massively impacts the outcome. Anaesthesia management for heart and lung transplant is quite demanding. In this article, we will review the various challenges encountered by an anaesthetist during the pre-, intra-, and postoperative period. The postoperative complications and its management will also be discussed briefly. [ABSTRACT FROM AUTHOR]

Blood, tissue and cell establishments (BTCs) stand out in the management of donor selection, procurement and processing of all types of substances of human origin (SoHO). In the last decades, the framework created around BTCs, including hospitals and national health system networks, and their links to research, development and innovation organizations and agencies have spurred their involvement in the study of groundbreaking advanced therapy medicinal products (ATMP). To further improve strategic synergies in the development of ATMPs, it will be required to promote intra- and inter-European collaborations by creating an international network involving BTCs and major stakeholders (i.e., research organizations, hospitals, universities, patient associations, public agencies). This vision is already shared with the European Blood Alliance, the association of non-profit blood establishments, with 26 member states throughout the European Union and European Free Trade Association states. Herein we present and analyze the "BTC for ATMP Development And Manufacture" (BADAM) model, an ethically responsible business model based on the values and missions of BTCs and their commitment to health equity, patient access and education (based on voluntary donation of SoHO to address unmet clinical needs, while contributing to training professionals and scientific literacy of our Society). The management model of blood, tissue and cell establishments (BTCs) for emerging uses of substances of human origin (SoHO) is characterized by its central role in the value chain. BTCs are strategically positioned between SoHO procurement (used as starting materials in the manufacture of advanced therapy medicinal products) and patient access in partner hospitals through synergies with their respective national health systems. [Display omitted] [ABSTRACT FROM AUTHOR]

• Sub-inhibitory concentrations of ampcilin, gentamycin, kanamycin, tetracycline, and naphthalene remarkably promoted plasmid conjugative transfer intra-genera. • Donors had key effects on transconjugants composition. • Stimulants induced a positive effect on conjugal transfer frequency in situ mating matrix, which may be associated with the enhanced expression of conjugative genes. • Blastocatella and Chitinimonas sp. were the main potential receptors of plasmid pND6-2 in activated sludge. The activated sludge process is characterized by high microbial density and diversity, both of which facilitate antibiotic resistance gene transfer. Many studies have suggested that antibiotic and non-antibiotic drugs at sub-inhibitory concentrations are major inducers of conjugative gene transfer. The self-transmissible plasmid pND6-2 is one of the endogenous plasmids harbored in Pseudomonas putida ND6, which can trigger the transfer of another co-occurring naphthalene-degrading plasmid pND6-1. Therefore, to illustrate the potential influence of stimulants on conjugative transfer of pND6-2, we evaluated the effects of four antibiotics (ampicillin, gentamycin, kanamycin, and tetracycline) and naphthalene, on the conjugal transfer efficiency of pND6-2 by filter-mating experiment. Our findings demonstrated that all stimulants within an optimal dose promoted conjugative transfer of pND6-2 from Pseudomonas putida GKND6 to P. putida KT2440, with tetracycline being the most effective (100 µg/L and 10 µg/L), as it enhanced pND6-2-mediated intra-genera transfer by approximately one hundred-fold. Subsequently, seven AS reactors were constructed with the addition of donors and different stimulants to further elucidate the conjugative behavior of pND6-2 in natural environment. The stimulants positively affected the conjugal process of pND6-2, while donors reshaped the host abundance in the sludge. This was likely because stimulant addition enhanced the expression levels of conjugation transfer-related genes. Furthermore, Blastocatella and Chitinimonas were identified as the potential receptors of plasmid pND6-2, which was not affected by donor types. These findings demonstrate the positive role of sub-inhibitory stimulant treatment on pND6-2 conjugal transfer and the function of donors in re-shaping the host spectrum of pND6-2. [Display omitted] [ABSTRACT FROM AUTHOR]

• Six new charge transfer complexes have been synthesized. • The complex structures exhibited a variety of morphologies. • The optimal stoichiometric ratio of donor to acceptor was confirmed to be 1:1. • C N and N H in the donor and COOH in the acceptor played a key role. Six new charge-transfer complexes using ofloxacin (OFL) and sulfamethazine (SMR) as electron donors and coumaric acid (COA), cinnamic acid (CNA), and salicylic acid (SAA) as acceptors via equimolar mixture have been synthesized. The experiment used UV–vis spectroscopy to determine the formation of the complex in methanol through the presence of a new broad absorption band with a maximum wavelength in the 200–400 nm range. The molecular composition of the charge-transfer complexes was determined by the spectrophotometric titration method and found to be 1:1 (donor: acceptor). These complexes have been characterized by infrared (FTIR) and scanning electron microscopy (SEM). In the FTIR spectra, the CT complexes showed a wavelength shift compared to the reactants. The complexes exhibited various morphologies by SEM, including spherical particles, short rods, and flattened shapes. Additionally, quantum chemical calculations at the DFT/B3LYP level of theory investigated the complexes' steady-state structures, energies, and charge densities. The intermolecular binding energies was negative, indicating that the reactions of the six complexes proceeded spontaneously. There was strong van der Waals forces and hydrogen bonds between the donor and acceptor, which contributed to the complexes' strong molecular stability. The C N and N H groups in the donor molecule, and the -COOH group in the acceptor molecule, played key roles in the complexation process. DFT calculation results were appropriate to support our experimental results. This study highlights the molecular mechanisms of donor and acceptor action in charge-transfer interactions, providing a theoretical basis for the synthesis of antibiotic complexes and the removal of antibiotics. [Display omitted] [ABSTRACT FROM AUTHOR]

In this study, we incorporated nanometal surface energy transfer (NSET) in lateral flow immunoassay (LFIA) and explored the relationship between fluorescence quenching efficiency and detection sensitivity to improve sensitivity of NSET-LFIA system. We developed nine gold nanoparticles (GNPs) with absorption spectrum in the range of 520–605 nm as acceptors and quantum dot microspheres (QDMs) with emission spectrum of 530, 570, and 610 nm as donors. By analyzing the overlap integral area, fluorescence quenching efficiency, and detection sensitivity of 27 donor-acceptor pairs, we observed that the larger overlap integral area led to higher fluorescence quenching efficiency and detection sensitivity. A maximum fluorescence quenching efficiency of 91.0% was obtained from the combination of GNPs at 605 nm and QDMs at 610 nm, achieving the highest detection sensitivity. We developed NSET-LFIA for the detection of T2 toxin with a limit of detection of 0.04 ng/mL, which was 10-times higher than that obtained via conventional GNP-LFIA. NSET-LFIA represents a versatile, ultrasensitive and valuable screening tool for small molecules in real samples. [Display omitted] [ABSTRACT FROM AUTHOR]

The left kidney is preferable in living donor nephrectomy (LDN). We aimed to investigate the safety and efficacy of right versus left LDN in both donor and recipients. A subgroup analysis of outcomes based on operative approach was also performed. A systematic review and meta-analysis was performed as per PRISMA guidelines. Outcomes of interest were extracted from included studies and analysed. There were 31 studies included with 79,912 transplants. Left LDN was performed in 84.1 % of cases and right LDN in 15.9 %. Right LDN was associated with reduced EBL (P = 0.010), intra-operative complications (P = 0.030) and operative time (P = 0.006), but higher rates of conversion to open surgery (1.4 % vs 0.9 %). However, right living donor renal transplantation (LDRT) had higher rates of delayed graft function (5.4 % vs 4.2 %, P < 0.0001) and graft loss (2.6 % vs 1.1 %, P < 0.0001). Graft survival was reduced in right LDRT at 3 years (92.0 % vs 94.2 %, P = 0.001) but comparable to left LDRT at 1- and 5-years. Otherwise, donor and recipient peri-operative outcomes and serum creatinine levels were comparable in both groups. Hand-assisted LDN was associated with shorter warm ischaemia time (P < 0.0001) but longer length of stay (LOS) than laparoscopic LDN and robotic-assisted LDN (P < 0.0001). RA-LDN was associated with less EBL and shorter LOS (both P < 0.0001) while patients who underwent L-LDN had a lower mean serum creatinine (SCr) level on discharge (P < 0.0001). Right LDRT has higher rates of delayed graft function and graft loss compared to left LDRT. Minimally-invasive surgical approaches potentially offer improved outcomes but further large-scale randomised controlled trials studies are required to confirm this finding. [Display omitted] • 31 studies with 79,912 transplants were included, 84.1% were left living donor nephrectomies (LDN) and 15.9% were right LDN. • Right LDN was associated with reduced estimated blood loss (EBL), intra-operative complications, and operative time. • Right living donor renal transplantation (LDRT) had higher rates of delayed graft function and graft loss. • Graft survival was reduced in right LDRT at 3 years but comparable to left LDRT at 1- and 5-years. • Robotic-assisted LDN was associated with less EBL and shorter length of stay compared to other operative approaches. [ABSTRACT FROM AUTHOR]

High anxiety among kidney transplant recipients has negative psychosocial consequences for health quality. This study aims to determine the risk factors that affect levels of anxiety in recipients of kidney transplants according to living and deceased donor types. The study was conducted using a descriptive correlational research method. The study conducted research with 330 kidney transplant recipients (from 261 live and 69 cadaver donors) who agreed to participate between February and July 2019. Participants completed the State-Trait Anxiety Inventory, which assesses state and trait anxiety. Participants had low state anxiety and moderate trait anxiety scores. A statistically significant, positive, moderate correlation was found between state anxiety scale and trait anxiety scale mean scores of recipients of kidney transplants from both living and deceased donors. According to a regression analysis of trait anxiety scores of transplant recipients from living donors, positive independent risk factors for anxiety include kidney transplant recipients with a low income, receiving kidneys from male donors, drug noncompliance, sleep disorders, and mental problems. Both kidney transplant recipients from living and deceased donors had low state anxiety and moderate trait anxiety. Nurses should develop effective intervention strategies that continue throughout life to reduce the anxiety of kidney transplant recipients. [ABSTRACT FROM AUTHOR]

Heart-lung transplantation (HLT) frequency has decreased over the years due to the fact that most right-sided heart failure can recover without heart-lung transplantation. However, there is still a subset of the patient population suffering from end-stage cardiopulmonary disease who would benefit from combined heart-lung transplantation. The main indication for continues to be pulmonary hypertension due to idiopathic pulmonary arterial hypertension or secondary to congenital heart disease, accounting for 60%-70% of heart-lung transplants during the past 3 decades. This paper provided updated detailed illustrated technique for combined pediatric and adult heart-lung transplantation practiced at Stanford University School of Medicine and Lucile Packard Children's Hospital at Stanford. A total of, 185 of combined heart-lung transplants have performed at our institution since 1990. [ABSTRACT FROM AUTHOR]

There are varied opinions in the United States regarding many aspects of care related to COVID-19. The purpose of this study was to examine the opinions of health care personnel and the policies of heart transplant centers concerning practices for the prevention and treatment of COVID-19 in donors and recipients of heart transplants. Two anonymous, electronic web-based surveys were developed: 1 was administered to health care personnel through a mailing list maintained by the Heart Failure Society of America (HFSA); another was administered to U.S. medical adult and pediatric heart transplant (HT) program directors. Individual and group e-mails were sent with an embedded link to the respective surveys in February 2022. A total of 176 individuals (8.6%) responded to the survey administered through the HFSA. Of medical directors of transplant programs, 78 (54% response rate) completed a separate survey on their centers' policies. Although 95% (n = 167) of individuals indicated vaccination against COVID-19 should be required prior to HT, only 67% (n = 52) of centers mandated that practice. Similarly, 61% of individuals thought vaccination should be required prior to HT for caregivers, but only 13% of transplant centers mandated caregiver vaccination. Of the centers, 63% reported considering donors despite histories of recent COVID-19 infection (within 3 months), and 47% considered donors with current positive polymerase chain reaction tests. Regarding post-transplant care, only 22% of programs routinely measured antibodies to COVID-19, and 71% used tixagevimab/cilgavimab (Evusheld) for pre-exposure prophylaxis. There were significant differences between individual preferences and centers' practices with respect to COVID-19 management of candidates for and recipients of HT. Additionally, there was wide variation in policies among centers, reflecting the need for further study to inform consistent guidance and recommendations across centers to optimize equitable care for this high-risk patient population. [ABSTRACT FROM AUTHOR]

The COVID-19 pandemic has significantly changed organ donation and transplantation worldwide. Since the beginning of the pandemic, the uncertainty regarding the potential route of transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created tremendous pressures on transplantation communities, and international organisations have advised against using organs from deceased donors who have tested positive for SARS-CoV-2. The possibility of SARS-CoV-2 transmission through organ donation has only been reported for lung transplantation; hence, based on current experience, transplantation of non-lung organs from donors with active SARS-CoV-2 infection has been considered possible and safe, at least over short-term follow-up. As the evolving outbreak of SARS-CoV-2 continues, alongside the presence of vaccines and new treatment options, clinicians should consider transplanting organs from deceased donors with active SARS-CoV-2 infection to recipients with limited opportunities for transplantation and those with specific natural or vaccine-induced immunity. This article proffers an expert opinion on the use of organs from deceased donors with resolved or active SARS-CoV-2 infection in the absence of more definitive data and standardised acceptance patterns. [ABSTRACT FROM AUTHOR]

Two dendritic nonlinear optical chromophores A-B based on the bis(3-hydroxypiperidin)aniline and bis(N-ethyl-N-hydroxyethyl)aniline donors and three 3,5-bis(benzyloxy)benzoic acid derivative isolation groups were designed and synthesized. The UV absorption, density functional theory (DFT) calculations, thermal stability, and electro-optic activity of these chromophores were systematically investigated in this article. The chromophores A-B exhibited good thermal stability at decomposition temperatures (T d) greater than 260 °C. Most importantly, steric hindrance groups could effectively reduce dipole-dipole interactions between molecules and improve the conversion efficiency of the first-order hyperpolarizability (β) of chromophores into large electro-optic (EO) coefficients (r 33). A large r 33 value of 236 p.m./V have been achieved for chromophore B. And the poling efficiency (2.79 ± 0.08 nm2/V2) of Chromophore B at 1310 nm was much higher than that of chromophore with single donor with similar structure. • Two dendritic nonlinear optical chromophores A-B with double donors had been synthesized. • Large r33 value of 176 and 236 pm/V have been achieved for film-A and film-B. • The poling efficiency of Chromophore B was much higher than chromophore with single donor. [ABSTRACT FROM AUTHOR]

Two innovative second-order nonlinear optical chromophores, designated as B–C, have been synthesized, featuring thiophene-derived donors and a tricyanovinyldihydrofuran bridge as acceptors. These chromophores have undergone comprehensive characterization. Notably, the donor components of chromophores B–C were (methyl(phenyl)amino)thiophene and (4-methoxyphenylamino)thiophene, respectively, in contrast to the diethylamino phenyl unit present in chromophore A. Density functional theory calculations suggested that the first hyperpolarizability of chromophore C, with a (methoxyphenyl amino) thiophene donor, was approximately 60 % higher than that of chromophores A and B. This indicates that merely substituting the benzene ring with thiophene does not significantly enhance the electron-donating ability of the donor. Polymeric thin films doped with 25 wt% of chromophores A-C exhibited r33 values of 39 p.m./V, 46 p.m./V, and 76 p.m./V, respectively. The electro-optic coefficients of chromophores B and C were 18 % and 95 % higher than that of chromophore A, respectively. These findings confirm that thiophene-derived donors, particularly those with multiple heteroatoms, can effectively enhance the electro-optical coefficient of chromophores. [Display omitted] • TCF based chromophores A-B with different double donors had been synthesized. • A large r 33 value (76 p.m./V) at 1310 nm have been achieved for film. • The decomposition temperatures of the three chromophores was higher than 220 °C. [ABSTRACT FROM AUTHOR]

Clinical characteristics of blood donors may affect short- and long-term outcomes of transfusion recipients. The impact of donor sex and age on recipient outcomes have not yielded consistent results in observational studies. One recently published randomized controlled trial (iTADS) addressing the impact of donor sex on recipient outcomes noted no differences between a female versus male transfusion strategy; a second Canadian multicenter trial has just been funded. Other donor characteristics - including pregnancy history, smoking status, obesity, and chronic illnesses - remain incompletely explored. More robust clinical studies with vein-to-vein capabilities are needed to understand the complex interplay between donors and recipients. [ABSTRACT FROM AUTHOR]

Objective In this study, we aimed to examine the perspectives of textile workers on organ donation and related factors. Method The sample of this descriptive and cross-sectional study consisted of employees of a textile factory located in eastern Turkey (n = 166). The data were collected using the forms Personal Information and determining Knowledge, Awareness, and Willingness regarding Organ Donation and Transplantation. Data collection forms were prepared by researchers based on the literature and taking expert opinion. In the analysis of the study data, number-percentage, chi-square test and Cramér's phi correlation analysis were used. Results The mean age of the participants was 21.10 ± 2.53, and the numbers of men and women were equal. It was determined that 63.3% of the participants needed education related to organ donation, and 57.8% were willing to donate their organs. There is a correlation the high levels of knowledge, awareness, and willingness regarding organ donation and transplantation with the participant's levels of thinking about donating their organs. Conclusion Our results supported the view that high levels of knowledge and awareness increased willingness about organ donation. In increasing the number of organ donors, high levels of knowledge and awareness are highly important, all parts of society should be provided with education on this issue, and it should be considered that workers of all sectors, especially textile workers, constitute a significant proportion of most societies in terms of numbers. [ABSTRACT FROM AUTHOR]

Organ transplantation is hampered by shortage of suitable organs. In countries with a legal framework, organ donation following euthanasia is an option labeled "donation after cardio-circulatory death category V" (DCD-V). We describe our experience with lung transplantation (LTx) after euthanasia and evaluate post-transplant outcome using a matched comparison to DCD-III (withdrawal from life-sustaining therapy) and donation after brain death (DBD). All bilateral LTx between 2007 and 2020 were retrospectively analyzed. Matching was performed for recipient age and gender, indication for LTx, mean pulmonary artery pressure, extracorporeal life support, and donor age, which resulted in 1:2 DCD-III and 1:3 DBD matching. Primary graft dysfunction (PGD), chronic lung allograft dysfunction (CLAD), and patient survival were analyzed. A total of 769 LTx were performed of which 22 from DCD-V donors (2.9%). Thirteen women and 9 men expressed their wish to become organ donor after euthanasia. Euthanasia request was granted for irremediable neuromuscular (N = 9) or psychiatric (N = 8) disorder or unbearable and unrecoverable pain (N = 5). PGD (grade 3, within 72 hours post-transplant) was 23.8% in the DCD-V cohort, which is comparable to DCD-III (27.9%; p = 1.00) and DBD (32.3%; p =.59). CLAD-free 3- and 5-year survival were 86.4% and 62.8%, respectively, and comparable to DCD-III (74.4% and 60.0%; p =.62) and DBD (72.6% and 55.5%; p =.32). Five-year patient survival was 90.9%, not significantly different from both DCD-III (86.0%; p = 1.00) and DBD (78.1%; p =.36). We observed that LTx with DCD-V allografts is feasible and safe, yielding no evidence for differences in short- and long-term outcome compared to matched cohorts of DCD-III and DBD. [ABSTRACT FROM AUTHOR]

Currently, no formal mechanisms or systematic approaches exist to inform developers of new vaccines of the evidence anticipated to facilitate global policy recommendations, before a vaccine candidate approaches regulatory approval at the end of pre-licensure efficacy studies. Consequently, significant delays may result in vaccine introduction and uptake, while post-licensure data are generated to support a definitive policy decision. To address the uncertainties of the evidence-to-recommendation data needs and to mitigate the risk of delays between vaccine recommendation and use, WHO is evaluating the need for and value of a new strategic alignment tool: Evidence Considerations for Vaccine Policy (ECVP). EVCPs aim to fill a critical current gap by providing early (pre-phase 3 study design) information on the anticipated clinical trial and observational data or evidence that could support WHO and/or policy decision making for new vaccines in priority disease areas. The intent of ECVPs is to inform vaccine developers, funders, and other key stakeholders, facilitating stakeholder alignment in their strategic planning for late stage vaccine development. While ECVPs are envisaged as a tool to support dialogue on evidence needs between regulators and policy makers at the national, regional and global level, development of an ECVP will not preclude or supersede the independent WHO's Strategic Advisory Group of Experts on Immunization (SAGE) evidence to recommendation (EtR) process that is required for all vaccines seeking WHO policy recommendation. Tuberculosis (TB) vaccine candidates intended for use in the adolescent and adult target populations comprise a portfolio of priority vaccines in late-stage clinical development. As such, TB vaccines intended for use in this target population provide a 'test case' to further develop the ECVP concept, and develop the first WHO ECVP considerations guidance. [ABSTRACT FROM AUTHOR]

The ecofriendly cellulose and gelatin provided sustainable and abundant sugars: d -ribofuranose, and 2-Deoxy-ribofuranose (starting reactants for preparative synthetic green chemistry pathways of charge transfer complexes. The natural available sugars d -ribofuranose, and 2-Deoxy-ribofuranose were obtained from facile hydrolysis of cellulose and gelatin natural macromolecules. Successive, low cost and facile alkaline- and acid hydrolysis of Deoxyribonucleic acid (DNA, from gelatin animal source) and ribonucleic acid (RNA, from cellulose plant source) yield the simple sugars: d -ribofuranose and 2-Deoxy-ribofuranose. Eight optically and biologically active charge transfer complexes were prepared from the reaction of the above sugars efficiently intercalated with two new prepared thiophene Schiff Lewis (electron donors) bases: 2-((2Hydroxybenzylidene) amino)-4, 5, 6, 7-tetrahydrobenzo [b] thiophene-3-carbonitrile (D1, 2-((Furan-2ylmethylene) amino) 4,5,6,7 tetrahydrobenzo [b] thiophene-3-carbonitrile (D2). The chemical structures of these prepared Schiff bases were confirmed using the mass spectra. The successful intercalation of the sugar units with the Lewis bases was ascertained using powder x ray diffraction. The molecular structures of the reaction products were proposed based on FTIR, 1H NMR. The optical activity of charge transfer complexes were confirmed using UV–Vis. Absorption spectroscopy. The surface morphology, microstructures, and particle size of the donors and charge transfer complexes were determined using scanning electron microscopy (SEM). The Lewis bases (D1) and (D2) showed no antimicrobial activity, while their charge transfer complexes showed good antimicrobial activity, suggesting their pharmaceutical and medicinal applications due to the potent biological activity against wide spread microbial microorganisms of Gram positive and Gram positive bacteria as well as some fungal species. [ABSTRACT FROM AUTHOR]

The demand for donor lungs continues to outpace the supply, yet nearly 75% of donor lungs intended for lung transplantation are discarded. We reviewed all donation after brain death organ donors listed within the UNOS Deceased Donor Database between 2005 and 2020. Univariable and multivariable analyses were run on the training set (n = 69,355) with the primary outcome defined as lung discard, and the results were used to create a discard risk index (DSRI). Discard data were assessed at DSRI value deciles using the validation set (n = 34,670), and differences in 1-year mortality were assessed using stratum-specific likelihood ratio (SSLR) analysis. Donor factors most associated with higher DSRI values included age > 65, PaO 2 < 300, hepatitis C virus, and cigarette use. Factors associated with lower DSRI values included donor age < 40 and PaO2 > 400. The DSRI was a reliable predictor of donor discard, with a C-statistic of 0.867 in the training set and 0.871 in the validation set. The DSRI was not a reliable predictor of 30-day, 1-year, 3-year, and 5-year survival following transplantation (C-statistic 0.519-0.530). SSLR analysis resulted in three 1-year mortality strata (SSLR 0.88 in the 1st DSRI value decile, 1.03 in the 2nd-5th, & 1.19 in the 6th-10th). The factors leading to lung allograft discard are not the same as those leading to worse recipient outcomes. This suggests that with proper allocation, many of the grafts that are now commonly discarded could be used in the future donor pool with limited impact on mortality. [Display omitted] [ABSTRACT FROM AUTHOR]

The storage of red blood cells for transfusion purposes induces modifications of biochemical and biological properties. Moreover, these modifications are modulated by the donors' characteristics and the cell processing. These ex vivo alterations were suspected to decrease the transfusion efficiency and even to induce adverse events. This short article will review the red blood cells storage lesions and the clinical data related to them. In particular, the questions regarding the donors and recipients sex will be discussed. [ABSTRACT FROM AUTHOR]

High signal-to-background ratio (SBR) monitoring of formaldehyde (FA) delivery in living systems is of great significance for the precise study of the physiological and pathological functions of FA. However, traditional FA donors mainly use fluorescent signals to monitor FA release, which hampers the high-performance bioimaging due to the undesirable background autofluorescence, leading to poor SBR and compromised imaging sensitivity. Herein, we present the first bioluminogenic donor B-FAD for esterase-activated FA release with high contrast bioluminescence imaging. By protecting the hydroxyl group of D-luciferin with acetoxymethyl ether group, B-FAD cannot be catalyzed by luciferase to emit light. In the presence of esterase, the ester bond of B-FAD breaks, producing FA and D-luciferin. B-FAD selectively and sensitively releases FA in the presence of esterase, accompanied by 34-fold bioluminescence enhancement. In addition, B-FAD has been successfully applied for FA delivery and bioluminescence imaging in living cells, with a SBR about 50 times higher than those obtained by fluorescence imaging. Therefore, in addition to providing an effective tool for imaging FA delivery in living cells, this work establishes a general approach for high contrast monitoring other reactive biological species release by easily changing the responsive unit on D-luciferin. [Display omitted] • A bioluminogenic donor B-FAD is synthesized for activated formaldehyde release. • B-FAD selectively and sensitively releases formaldehyde in the presence of esterase. • B-FAD displays high signal-to-background ratio monitoring of formaldehyde release in living cells. • The donor system can expand to high contrast monitoring of other reactive biological species release. [ABSTRACT FROM AUTHOR]

What meanings do donor conceived young adults give to direct-to-consumer DNA testing, and how does direct-to-consumer DNA testing relate to their lived experiences? Thirty-three young adults participated in in-depth interviews in November 2020 and September 2021 as part of a study of donor conceived people in the UK that focuses on the period of young adulthood. All participants were aged between 18 and 31 years, had been conceived by sperm donation at a time of legal donor anonymity, and were mainly resident in the UK. Interviews were analysed using reflexive thematic analysis. Nineteen participants (58%) had used at least one direct-to-consumer DNA test, and 14 (46%) had not. Three participants (9%) had learned about their donor conception inadvertently through a direct-to-consumer DNA test. Twelve participants (36%) had matched with their donor, someone conceived using the same donor, or both. Four related themes that capture participants' perspectives and experiences of direct-to-consumer DNA testing were identified: ruptures, disclosures, webs and temporalities. To the authors' knowledge, this is the first study to evidence both active interest and disinterest in direct-to-consumer DNA testing among individuals who are donor conceived. The meanings ascribed to, and uses of, direct-to-consumer DNA testing vary significantly among donor conceived young adults. Findings relating to the relationship between 'informal' and 'formal' information systems, and the absence of guidance and support for those using direct-to-consumer DNA tests, should be considered carefully by practitioners, regulatory bodies and policymakers going forward. [ABSTRACT FROM AUTHOR]

Surveillance of allograft health after transplantation has traditionally relied on biopsy procedures that enable pathologic assessment for acute rejection. Noninvasive methods to assess for graft injury have been developed and tested over the past decade, and now offer a convenient way to reduce reliance on invasive testing and improve patient satisfaction. Emerging evidence suggests that detection of allograft injury via donor-derived cell-free DNA (dd-cfDNA) may, in fact, have better sensitivity compared to traditional biopsy-based strategies. This state-of-the-art review describes the development, testing, and current use of dd-cfDNA assays for acute rejection monitoring after heart transplantation, and discusses innovative ways that such assays can be used for personalized patient management. [ABSTRACT FROM AUTHOR]

To report the anatomic and functional outcomes of autologous retinal transplantation (ART). Multicenter, retrospective, interventional, consecutive case series. One hundred thirty eyes of 130 patients undergoing ART for the repair of primary and refractory macular holes (MHs), as well as combined MH-rhegmatogenous retinal detachment (MH-RRD), between January 2017 and December 2019. All patients underwent pars plana vitrectomy and ART, with surgeon modification of intraoperative variables. A large array of preoperative, intraoperative, and postoperative data was collected. Two masked reviewers graded OCT images. Multivariate statistical analysis and subgroup analysis were performed. Macular hole closure rate, visual acuity (VA), external limiting membrane and ellipsoid zone (EZ) band integrity, and alignment of neurosensory layers (ANL) on OCT. One hundred thirty ART surgeries were performed by 33 vitreoretinal surgeons worldwide. Patient demographics were: mean age of 63 ± 6.3 years, 58% female, 41% White, 23% Black, 19% Asian, and 17% Latino. Preoperative VA was 1.37 ± 0.12 logarithm of the minimum angle of resolution (logMAR; Snellen equivalent, approximately 20/500), which improved significantly to 1.05 ± 0.09 logMAR (Snellen equivalent, approximately 20/225; P < 0.001) after surgery (mean follow-up, 8.6 ± 0.8 months). Autologous retinal transplantation was performed for primary MH repair in 27% of patients (n = 35), for refractory MH in 58% of patients (n = 76; mean number of previous surgeries, 1.6 ± 0.2), and for MH-RRD in 15% of patients (n = 19). Mean maximum MH diameter was 1470 ± 160 μm, mean minimum diameter was 840 ± 94 μm, and mean axial length was 24.6 ± 3.2 mm. Overall, 89% of MHs closed (78.5% complete; 10% small eccentric defect), with a 95% closure rate in MH-RRD (68.4% complete; 26.3% small eccentric defect). Visual acuity improved by at least 3 lines in 43% of eyes and by at least 5 lines in 29% of eyes. Reconstitution of the EZ (P = 0.02) and ANL (P = 0.01) on OCT were associated with better final VA. Five cases of ART graft dislocation (3.8%), 5 cases of postoperative retinal detachment (3.8%), and 1 case of endophthalmitis (0.77%) occurred. In this global experience, patients undergoing ART for large primary and refractory MHs and MH-RRDs achieved good anatomic and functional outcomes, with low complication rates despite complex surgical pathologic features. [ABSTRACT FROM AUTHOR]

Access to safe water is a significant issue in developing countries. Myanmar, a developing country in Southeast Asia, receives aid from many Organization for Economic Co-operation and Development (OECD) member countries. Installation of point-of-use water treatment devices is an example of a water aid project to update the water infrastructure of the recipient country. However, research has tended to ignore the circumstances of the recipient. Usually, they already conduct water treatment and provide water for daily use; therefore, comparison of newly installed technology with currently used technology is important to achieve sustained use of the new technology. In this study, 99 households in a village near Yangon City were asked to complete a questionnaire survey. The questionnaire included basic household information, currently used local technology, and residents' perception of newly installed technologies from donor countries. The outcome of the study showed that local people were interested in higher water quality from both current and newly installed technologies, and they had different expectations of different donor countries. They were concerned about costs with all countries, but had different expectations for quality and ease of use from different countries. Analysis of specific technologies suggested that local people recognized the similarity of donor countries A (Japan) and B (China), but they expected higher quality from donor A and lower cost from donor B. Further analysis regarding current technology implied that they preferred to receive, and were more willing to use, technology from donor country A than from donor country B due to perceived quality. [ABSTRACT FROM AUTHOR]

The internal maxillary artery (IMAX) is currently considered one of the main donor vessels in extracranial-to-intracranial bypass surgeries. Four main techniques for harvesting the IMAX have been described: via the anterior medial infratemporal fossa (AMITF), the middle infratemporal fossa (MITF), the anterior lateral middle fossa (ALMF), and the lateral middle fossa (LMF). The advantages and limitations of these techniques have not yet been systematically evaluated and compared. Twenty-five cadaver specimens were used to evaluate the harvesting technique. The length and the caliber of the targeted IMAX segments, as well as the depth from the operating plane to the IMAX, surgical time, and surgical area of exposure, were analyzed. The MITF technique provided the greatest operating area of exposure (mean, 3.88 ± 0.97 cm2). The LMF and MITF techniques provided the largest IMAX caliber (mean, 3.1 ± 0.4 mm and 3.0 ± 0.3 mm, respectively). The ALMF technique provided the shallowest operative depth as well as the least time of exposure (21.8 minutes). The MITF technique exposed the longest IMAX segment (mean, 18.8 ± 3.5 mm). Advantages of the AMITF and MITF techniques include anatomic simplicity, absence of skull base drilling, and greater discretion in muscle dissection. These properties can simplify the anastomosis procedure compared with the ALMF and LMF techniques. Identification of the IMAX pattern is important before selecting the approach for this bypass operation. [ABSTRACT FROM AUTHOR]

The advent of therapies for successful treatment of hepatitis C virus has allowed the heart and lung transplant community to re-explore the use of hepatitis C virus–positive donors for organ transplantation, with a benefit for many terminally ill patients. The consensus statements provided herein represent the current state of knowledge and expertise in this area, which we expect will continue to rapidly evolve over the next few years. [ABSTRACT FROM AUTHOR]

The number of potential pediatric heart transplant recipients continues to exceed the number of donors, and consequently the waitlist mortality remains significant. Despite this, around 40% of all donated organs are not used and are discarded. This document (62 authors from 53 institutions in 17 countries) evaluates factors responsible for discarding donor hearts and makes recommendations regarding donor heart acceptance. The aim of this statement is to ensure that no usable donor heart is discarded, waitlist mortality is reduced, and post-transplant survival is not adversely impacted. [ABSTRACT FROM AUTHOR]

• Quality of life in adult patients after hematopoietic stem cell transplantation in childhood was good. • Sibling donor-recipient relationship is unbalanced with higher level of rivalry presented among donors. • Further multicenter studies are necessary to assess all aspects of sibling relationship years after transplantation experience and finally to provide effective psychological interventions for an often overlooked population of pediatric sibling donors. Despite the fact that the choice of donors and the number of sources of hematopoietic stem cells have increased, a sibling remains a preferred donor for allogeneic hematopoietic stem cell transplantation (HSCT). Transplant donation between siblings is a unique life experience that may have an impact on their future relationship. The aim of the study was to quantitatively measure the quality of life (QoL) in patients who underwent transplant and to describe the relationship between a recipient and a sibling donor after HSCT. We identified and invited 82 adults aged 18.0 to 38.7 years (median, 23.6) who underwent HSCT in our center and their sibling donors to participate in this survey. Forty-five patients (54.9%) and their siblings consented to take part in the study. The studied group consisted of 45 matched siblings donor (MSD)-HSCT recipients (19 women and 26 men) aged 18.0 to 36.2 (median, 28.5) years, who underwent MSD-HSCT at the age of 5.8 to 16.3 (median, 11.9) years, and their sibling donors aged 21.0 to 36.0 (median, 31.0) years, who were aged 11.2 to 20.2 (median, 15.5) years at bone marrow harvesting. For QoL and sibling relationship assessment, we used the Functional Assessment of Cancer Therapy–Bone Marrow Transplantation (FACT-BMT) and the Adult Sibling Relationship Questionnaire (ASQR). Higher scores indicate better quality of life in each scale of the FACT-BMT and the more significant is the factor in a sibling relationship measured by the ASQR. The questionnaires were given to both subgroups, HSCT recipients and donors, and the results were compared with each other. The overall result of the FACT-BMT questionnaire was 117 ± 35.0. The highest QoL was found in the functional (25.0 ± 3.5) and social well-being (25.0 ± 3.5) subscales, whereas the worst was in the emotional well-being (18.0 ± 9.5) subscale. Statistically, the QoL score was not influenced by current age (P =.378), age at the moment of HSCT (P =.256), and sex (P =.117). Being a recipient or a donor of HSCT was not a significant factor associated with warmth (2.6 ± 0.5 versus 3.1 ± 0.5; P =.830) and conflict (2.0 ± 0.7 versus 2.1 ± 1.2; P =.886) within the sibling relationship, whereas recipients scored significantly lower in rivalry within the sibling relationship compared with HSCT donors (0.8 ± 0.3 versus 1.2 ± 0.2; P =.012). The FACT Treatment Outcome Index remained the only significant predictor of warmth in the sibling relationship between HSCT recipient and donor. QoL in adult patients after HSCT in childhood was good. Sibling donor-recipient relationship is unbalanced, with a higher level of rivalry presented among donors. Further multicenter studies based on a larger cohort of patients are necessary to assess all aspects of the sibling relationship after transplantation experience. [ABSTRACT FROM AUTHOR]

Small molecules and polymer derivatives based on fused ring system of dibenzo[ b,d ]thiophene, dibenzo[ b,d ]silole, dibenzo[ b,d ]furan, dibenzo[ b,d ]germole, dibenzo[ b,d ]selenophene and dibenzo[ b,d ]tellurophene are efficient donor (D) materials for bulk heterojunction organic solar cell (BHJ-OSCs) applications. Dibenzo based hetero-tricyclic fused ring systems showed poor PCE than other ring system due to low π-conjugation, disorder in structure, poor solubility, higher d-spacing of π-π stacking in thin film state, low hole mobility and air stability. To further improve the power conversion efficiency (PCE) of fused ring derivatives, we have to incorporate heteroatoms (P-block elements N, S, Si, Ge, Ga, Sn, and Se) and tailor three member ring based donor system. This review briefly summarizes the data on fused ring system based small molecules or polymers for BHJ-OSCs application and gives suggestion to design new donor materials with desired properties. Image 10 • The dibenzo based oligomer and polymeric donor molecules for efficient BHJ-OSCs applications has been reviewed. • The reasons behinds low power conversion efficiency of dibenzo based donor for organic active materials in OSCs. • Various heteroatoms substituted dibenzo donors' derivative photovoltaic properties are detail reviewed. • Possible molecular engineering of active material in BHJ-OSCs to achieve high PCE. [ABSTRACT FROM AUTHOR]

• The best donor options for patients with primary immunodeficiencies (PIDs) are often unrelated or older, HLA-haploidentical donors • Inherited diseases, particularly autosomal dominant, can diminish related donor options • Additional evaluations, such as genetic testing, add complexity to donor searches for patients with PIDs. Patients with primary immunodeficiencies (PIDs) are potentially cured by allogeneic hematopoietic cell transplantation (HCT). The spectrum of PIDs has expanded greatly beyond those that present in infancy or are diagnosed on newborn screening and require urgent, preemptive HCT. Many PID diagnoses are now made later in life, and the role of HCT is only considered for severe disease manifestations; in these cases, the kinetics and goals of a donor search may be different than for severe combined immunodeficiency. Across all PIDs, related donor searches have the additional selection factor of the inherited disease, and such searches may yield more limited options than searches for patients with hematologic malignancies; thus, unrelated donor options often become more critical in these patients. We retrospectively evaluated the outcomes of donor searches among patents with PIDs referred for HCT at the National Institutes of Health, where the minimum patient age for evaluation is 3 years and where donor options include matched sibling donors or matched related donors, HLA-haploidentical (haplo), or 7-8/8 HLA matched unrelated donors (mMUDs/MUDs). Patient (n = 161) and donor demographics, MUD search results, HLA typing, pedigrees, mutation testing, and donor selection data were collected. The National Marrow Donor Program HapLogic 8/8 HLA match algorithm was used to predict the likelihood of a successful MUD search and categorized as very good, good, fair, poor, very poor, or futile per the Memorial Sloan Kettering Cancer Center (MSKCC) Search Prognosis method. There were significant differences by PID mode of inheritance in patient age, disposition (receipt of HCT or not), donor source, and donor relatedness. A related or unrelated donor option could be identified for 94% of patients. Of living first-degree relatives (median, 3; range, 0 to 12 per patient), a median of 1 donor remained for autosomal dominant and X-linked (XL) diseases after HLA typing, mutation testing, and other exclusions, and a median of 2 donors remained for autosomal recessive (AR) diseases. Among patients with a PID of known mode of inheritance (n = 142), the best related donor was haplo for 99 (70%) patients, with 56 (39%) haplos age 40 years or older and 5 (4%) second-degree haplos; 13 (9%) had no family donor options. The best related donor was a heterozygote/asymptomatic carrier of the PID mutation in 36 (49%) patients with AR or XL disease (n = 73). Among patients with MUD search performed (n = 139), 53 (38%) had very poor/futile 8/8 MUD searches, including 6 (32%) of those with unknown PID mutation and therefore no family donor options. The MSKCC Search Prognosis was less favorable for those of non-European ancestry compared with European ancestry (P =.002). Most patients of Hispanic or African ancestry had very poor/futile MUD searches, 71% and 63%, respectively. No HCT recipients with very poor/futile MUD searches (n = 38) received 8/8 MUD grafts. Alternative donor options, including haplo and unrelated donors, are critical to enable HCT for patients with PIDs. MUD search success remains low for those of non-European ancestry, and this is of particular concern for patients with PIDs caused by an unknown genetic defect. Among patients with PIDs, related donor options are reduced and haplos age 40 years and older and/or mutation carriers are often the best family option. [ABSTRACT FROM AUTHOR]

• The type of donor (sibling versus MUD versus haplo) is not associated with outcomes after a clofarabine-based RIC regimen for myeloid malignancies. • Our data suggest that haploidentical donors are an acceptable alternative for patients receiving a clofarabine-based RIC PBSC allograft for myeloid malignancies who lack an MSD or a MUD. • Myelodysplastic syndrome (versus AML), high disease risk index, and older donor (≥50 years) were associated with lower OS and DFS. Clofarabine-based reduced-intensity conditioning (RIC) regimens are well-established schedules for allograft in patients with myeloid malignancies. A retrospective study was conducted including all adults allografted in our department with such a regimen and disease with the aim to assess whether or not the donor type (matched sibling [MSD], matched unrelated [MUD], or haploidentical [haplo]) impacted outcomes. Between October 2009 and February 2018, 118 patients met the inclusion criteria. Thirty-six, 55, and 27 patients received a graft from an MSD, MUD, or haplo donor, respectively. Peripheral blood stem cells (PBSCs) were the source of graft for all patients. The median age of the entire cohort was 62 years (range, 20 to 73), and the median follow-up was 31 months (range, 4.5 to 106). All patients engrafted except 1 haplo recipient. Neutrophils (>.5 × 109/L) and platelets (50 × 109/L) recoveries were significantly delayed in the haplo group (P =.0003 and P <.0001) compared with MSD and MUD. Acute grades II to IV or III to IV graft-versus-host disease (GVHD) incidences were similar between the 3 groups as well as the incidence of moderate or severe chronic GVHD. Also, similar 2-year overall survival (OS; 64.7% versus 73.9% versus 60.2%, P =.39), disease-free survival (DFS; 57.7% versus 70.9% versus and 53.6%, P =.1), and GVHD relapse-free survival (37.9% versus 54.3% versus 38.9%, P =.23) were observed between MSD versus MUD versus haplo groups. The same was true when considering only acute myeloid leukemia (AML) cases. In multivariate analysis the type of donor remained independent of outcomes in this series, whereas myelodysplastic syndrome (versus AML), high disease risk index, and older donor (≥50 years) were associated with lower OS and DFS. These data suggest that haplo donors are an acceptable alternative for patients receiving a clofarabine-based RIC PBSC allograft for myeloid malignancies who lack an MSD or a MUD. [ABSTRACT FROM AUTHOR]

The availability of solid organs for transplantation remains low and there is a substantial need for methods to preserve the viability of grafted tissues. Suppression of solid-organ transplant rejection has traditionally focused on highly effective T cell inhibitors that block host immune lymphocyte responses. However, persistent and destructive innate and acquired immune reactions remain difficult to treat, causing late graft loss. Pretreatment of grafts to reduce organ rejection provides an alternate strategy. Approaches using antithrombotics, stem cells, genetic modifications, modulation of infrastructural components (connective tissue, CT; glycocalyx) of donor organs, and engineering of new organs are under investigation. We discuss here new approaches to modify transplanted organs prior to engraftment as a method to reduce rejection, focusing on the CT matrix. There is an urgent need to increase the number of organs available for transplantation. Modifying donor organs before transplantation, instead of treating the recipient, is an attractive approach to increasing the number of available organs. Perfusion with next-generation, multifunctional antithrombotic agents, biologic and genetic modulation of the complement cascade, and modification of the CT glycosaminoglycans in the donor graft before transplantation may prolong graft survival and reduce rejection. Stem cell transplants to repair injured or dying organs, and transplantation of genetically modified xenografts, may expand the availability of donor organs. Modern advances in engineered biomaterials with highly tuned CT scaffolds allow highly matched reconstruction of donor organs. [ABSTRACT FROM AUTHOR]

Uterus transplantation to treat absolute uterine factor infertility is a rapidly evolving field still at its early clinical experimental stage. Most human uterus transplantation attempts and live births have been after transplantation with uteri from live donors, who, in most cases, are closely related to the recipient. However, successful transplant with live births after uterus transplantation from deceased donors has also been reported. This article discusses the pros and cons in relation to live and deceased donors for uterus transplantation. [ABSTRACT FROM AUTHOR]

• A comparation between P3HT and PDCBT with a tiny structure difference were investigated based on MD simulations and DFT calculations in non-fullerene OSCs. • V OC , absorption spectra, and the hole mobility which is in relation to the ability of charge transport were researched in depth. • By considering both of electron and hole transfer processes, the interface CS/CR rates were calculated. The PDCBT shows much better performance than P3HT in non-fullerene organic solar cell although the former only replaces hexyl by alkoxycarbonyl group compared with the latter. In this work, we will focus on this tiny difference in structure and huge difference in performance between these two polymers from theoretical perspective. Thus we present a comparative study based on the dependent/time-dependent density functional theory (DFT/TDDFT) calculations and molecular dynamic (MD) simulations. The results reveal that PDCBT not only possesses lower molecular orbital energy levels which leads to the increasement of the open circuit voltage (V OC), but also exhibits better planarity and larger hole mobility than P3HT. In particular, comparing with P3HT system, PDCBT system also displays the higher charge separation rate and smaller charge recombination rate both in hole transfer and electron transfer process at the interface, which promote the enhancement of short-circuit current density. Therefore, this work provides a fundamental understanding of the prominent influence of the replacement of hexyl group by alkoxycarbonyl in P3HT on the cell performance and also provides some theoretical guidance for further optimization of donor materials in non-fullerene organic solar cells (OSCs). [ABSTRACT FROM AUTHOR]